Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12104335 | 0.91 | ALDH1A1 (0.51) | ALDH1A1KMT2ARXFP1TSHREPHX1 | |
| SCHEMBL6058547 | 0.85 | EPHX1 (0.53) | ALDH1A1KMT2ARXFP1TSHREPHX1 | |
| SCHEMBL6229787 | 0.84 | ALDH1A1 (0.43) | ALDH1A1KMT2ARXFP1EPHX1NPC1 | |
| SCHEMBL6228100 | 0.84 | ALDH1A1 (0.43) | ALDH1A1KMT2ARXFP1EPHX1NPC1 | |
| SCHEMBL6058833 | 0.83 | RXFP1 (0.57) | ALDH1A1KMT2ARXFP1TSHREPHX1 | |
| SCHEMBL6058360 | 0.82 | KMT2A (0.48) | ALDH1A1KMT2ARXFP1TSHREPHX1 | |
| SCHEMBL5805076 | 0.79 | ALDH1A1 (0.50) | ALDH1A1KMT2ARXFP1TSHRRAB9A | |
| SCHEMBL5608005 | 0.79 | TSHR (0.47) | ALDH1A1KMT2ARXFP1TSHREPHX1 | |
| SCHEMBL29602546 | 0.79 | TSHR (0.47) | ALDH1A1KMT2ARXFP1TSHREPHX1 | |
| SCHEMBL9915219 | 0.79 | ALDH1A1 (0.47) | ALDH1A1KMT2ATSHREPHX1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024349-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20150231141-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2015-08-20 | — | — | US | disclosed |
| US-9006275-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8716284-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-05-06 | — | — | US | disclosed |
| US-8716284-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-05-06 | — | — | US | disclosed |
| US-8716284-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-05-06 | — | — | US | disclosed |
| EP-2310356-B1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2013-08-14 | — | — | EP | disclosed |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2013-07-18 | — | — | US | disclosed |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2013-07-18 | — | — | US | disclosed |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2013-07-18 | — | — | US | disclosed |
| EP-2024349-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Abbott Laboratories (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | SCHREINER PETER R | 2008-11-06 | — | — | US | disclosed |
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | SCHREINER PETER R | 2008-11-06 | — | — | US | disclosed |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| WO-2007140439-A2 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |
| EP-0897747-B1 | NITRATION OR CARBOXYLATION CATALYSTS | DAICEL CHEM (JP) | 2006-04-05 | — | — | EP | disclosed |
| EP-1574494-A1 | Adamantane derivative | Daicel Chemical Industries, Ltd. (JP) | 2005-09-14 | — | — | EP | disclosed |
| EP-1574495-A1 | Adamantane derivatives | Daicel Chemical Industries, Ltd. (JP) | 2005-09-14 | — | — | EP | disclosed |
| US-6468487-B1 | SUCH AS N-HYDROXYPHTHALIMIDE; DIRECTLY AND EFFICIENTLY REACTING ADAMANTANE WITH NITROGEN OXIDE OR WITH CARBON MONOXIDE AND OXYGEN | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-10-22 | — | — | US | disclosed |
| EP-0897747-A1 | NITRATION OR CARBOXYLATION CATALYSTS | Daicel Chemical Industries, Ltd. (JP) | 1999-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231141-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | ALDH1A1 1171/4885KMT2A 2140/4885RXFP1 164/4885 |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | ALDH1A1 121/4885KMT2A 2991/4885RXFP1 722/4885 |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | OPRL1, OPRK1, OPRD1 | ALDH1A1 81/4885KMT2A 2711/4885RXFP1 737/4885 |
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | GABRA5, GABRA1, GABRA4 | ALDH1A1 570/4885KMT2A 3097/4885RXFP1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.